...
首页> 外文期刊>Journal of Diabetes Science and Technology >System Accuracy Assessment of a Blood Glucose Meter With Wireless Internet Access Associated With Unusual Hypoglycemia Patterns in Clinical Trials
【24h】

System Accuracy Assessment of a Blood Glucose Meter With Wireless Internet Access Associated With Unusual Hypoglycemia Patterns in Clinical Trials

机译:在临床试验中具有无线互联网接入的血糖仪的系统准确性评估与异常的低血糖模式相关联

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: In recent randomized clinical trials, an unusual reporting pattern of glycemic data and hypoglycemic events potentially related to an internet enabled blood glucose meter (MyGlucoHealth, BGM) was observed. Therefore, this clinical study was conducted to evaluate the system accuracy of the BGM in accordance with the ISO15197:2015 guidelines with additional data collection. Methods: To investigate system accuracy, 10 of 3088 devices and 6 of 23 strip lots, used in the trials, were selected by a randomization procedure and a standard repeatability assessment. YSI 2300 STAT Plus was used as the standard reference method. The samples were distributed as per the ISO15197:2015 recommendations with 20 additional samples in the hypoglycemic range. Each sample was tested with 6 devices and 6 strip lots with double determinations. Results: Overall, 121 subjects with blood glucose values 26-423 mg/dL were analyzed, resulting in 1452 data points. In all, 186/1452 readings (12.8%) did not meet the ISO acceptance criteria. Data evaluated according to the FDA guidelines showed that 336/1452 (23.1%) readings did not meet the acceptance criteria. A clear bias toward elevated values was observed for BG <100 mg/dL (MARD: 11.0%). Conclusions: The results show that the BGM, although approved according to standard regulatory guidelines, did not meet the level of analytical accuracy required for clinical treatment decisions according to ISO 15197:2015 and FDA requirements. In general, caution should be exercised before selection of BGMs for patients and in clinical trials.
机译:背景:在最近的随机临床试验中,观察到与互联网血糖仪(MyGlucoHealth,BGM)潜在相关的血糖数据和降血糖事件的异常报告模式。因此,根据ISO15197:2015指南进行了这项临床研究,以评估BGM的系统准确性,并收集了其他数据。方法:为调查系统准确性,通过随机化程序和标准重复性评估选择了试验中使用的3088台设备中的10台和23批中的6台。 YSI 2300 STAT Plus被用作标准参考方法。样品按照ISO15197:2015的建议进行分配,并在降血糖范围内增加了20个样品。每个样品都用6台设备和6批试纸进行了双重测定。结果:总共分析了121位血糖值为26-423 mg / dL的受试者,得出1452个数据点。总计186/1452读数(12.8%)不符合ISO接受标准。根据FDA指南评估的数据显示336/1452(23.1%)读数不符合接受标准。对于BG <100 mg / dL(MARD:11.0%),观察到明显的偏高值。结论:结果表明,BGM尽管已根据标准法规指南批准,但未达到根据ISO 15197:2015和FDA要求进行临床治疗决策所需的分析准确性水平。通常,在为患者选择BGM之前和在临床试验中应谨慎行事。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号